TENX - Tenax Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue--49.286
Cost of Revenue---
Gross Profit--49.286
Operating Expenses
Research Development3,527.31713,139.6816,660.387
Selling General and Administrative5,678.5816,245.9587,170.779
Non Recurring-33,265.11,034.863
Total Operating Expenses---
Operating Income or Loss-9,205.898-52,650.739-14,816.743
Income from Continuing Operations
Total Other Income/Expenses Net366.216764.735784.012
Earnings Before Interest and Taxes-8,839.682-51,886.004-14,032.731
Interest Expense--49.081
Income Before Tax-8,839.682-51,886.004-14,081.812
Income Tax Expense--7,962.1-
Minority Interest---
Net Income From Continuing Ops-8,839.682-43,923.904-14,081.812
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-8,839.682-43,923.904-14,081.812
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-8,839.682-43,923.904-14,081.812